Beone Medicines Ltd (ONC) - News Archive

Biopharmaceutical advances continue to transform the landscape of cancer treatment, offering new hope where traditional therapies have fallen short. In this article, we delve into the latest developments surrounding BeO...

BeOne Medicines: Pioneering Advances in Oncology with Promising Data from ASH 2025 and ESMO 2025 SAN CARLOS, California BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235) is poised to maintain its status as a...

In a significant advancement for oncology, BeOne Medicines Ltd., recognized for its innovative approaches in cancer treatment, has recently announced compelling results from its Phase-3 clinical trials. These results un...

SAN CARLOS, Calif. , October 22, 2025 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a leading player in global oncology, has made significant strides in lung cancer treatments with its latest presentatio...

SAN CARLOS, Calif. BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a pioneering global oncology company, has announced a significant milestone in its clinical development programme. The U.S. Food and Drug...

Sonrotoclax Gains Breakthrough Therapy Designation; TEVIMBRA Approved in Europe for NSCLC Treatment BeOne Medicines Achieves Key Regulatory Milestones in Oncological Advancements In a significant stride for oncological...

: The field of oncology continues to evolve at an unprecedented pace with transformative therapeutic strategies emerging to address various malignancies. Recently, BeOne Medicines Ltd., a globally recognized oncology co...

BeOne Medicines Secures European Approval for TEVIMBRA in NSCLC Treatment and Continues Breakthroughs in Oncology Pipeline The biopharmaceutical landscape in oncology has seen significant advancements with BeOne Medicin...

: The recent approval of TEVIMBRA (tislelizumab) by the European Commission marks a significant advancement in the treatment of resectable non-small cell lung cancer (NSCLC). Despite this breakthrough, the financial rea...

BeOne Medicines: Pioneering Oncology Innovations with PRIME Designation and Groundbreaking Research at EHA 2025SAN CARLOS, Calif. In a significant development for the oncology sector, BeOne Medicines Ltd. (NASDAQ: ONC;...

Abstract: This article provides an analysis of recent developments in oncology research as presented by BeOne Medicines Ltd. during their Investor R&D Day. The event showcased significant progress in the company’s oncol...

Abstract: BeOne Medicines Ltd., a prominent global player in oncology, recently showcased significant advancements in its pipeline during a highly anticipated Investor R&D Day held in San Carlos, California. The company...

The landscape of oncology treatment continues to evolve as the U.S. Food and Drug Administration (FDA) recently approved TEVIMBRA (tislelizumab-jsgr), a monoclonal antibody, for the first-line treatment of adults with u...

Unlocking New Horizons in Hematology: Breakthroughs by BeOne Medicines and BeiGene San Carlos, California In a major stride within the oncology sector, BeOne Medicines Ltd. (traded on NASDAQ: ONC, HKEX: 06160, SSE: 6882...

In a groundbreaking development for oncology therapeutics, BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235) announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of...

Innovative Progress in Oncology: BeOne Medicines SEQUOIA Trial Highlights BRUKINSA s Effectiveness in Frontline CLL Treatment BeOne Medicines Ltd. (NASDAQ: ONC, HKEX: 06160, SSE: 688235), a key player in global oncology...

In the rapidly evolving landscape of oncology, innovations are continually reshaping our understanding and treatment of various cancer types. Among the frontrunners in this crucial field, BeiGene, Ltd. (recently rebrand...

In a groundbreaking announcement poised to redefine treatment paradigms in oncology, BeiGene, Ltd. soon to be BeOne Medicines Ltd. will present an impressive lineup of 23 abstracts at the 2025 American Society of Clinic...

BeiGene Halts Ociperlimab Clinical Development Following Data Monitoring Committee Review San Carlos, California BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company soon to be rebranded as B...

In the world of oncology, breakthroughs happen not just in labs but also in regulatory corridors, adding hope where it was previously just a flicker. BeiGene, a rising star in the global oncology landscape, has just bee...